Dr. Gregg Siegal, Chief Scientific Officer at ZoBio said “We are clearly happy that CellCentric has chosen ZoBio as a partner in this challenging project. Epigenetics is an exciting, yet challenging, field. We feel that our unique combination of biophysical and biochemical approaches yields significant advantages in developing small molecule inhibitors of these targets with optimal drug-like properties.”
Dr Anthony Brown, Scientific Director at CellCentric, said “The ZoBio TINS technology offers a unique opportunity to identify novel hit matter against our epigenetic drug targets. The interaction with ZoBio will allow us to expand the breadth of our hit finding capabilities and will accelerate our on-going drug discovery activities. We are delighted to enter into this agreement to screen against these novel and exciting epigenetic drug targets.”
CellCentric is a drug discovery company focused on targeting epigenetic processes for new treatments for cancer. The company identifies novel cellular mechanisms and targets which it then prioritises and takes into small molecule drug discovery. Active programmes include inhibitors to histone methyltransferases and epigenetic enzymes that act via ubiquitination. The company benefits from relationships with a global network of leading researchers.
About ZoBio BV
Starting with its core TINS (Target Immobilized NMR Screening) fragment screening technology, ZoBio provides an array of biophysics services to support fragment-based drug discovery. These services form an integrated pipeline that includes fragment discovery, validation/characterisation by orthogonal methods such as SPR, and NMR-based structural biology services. ZoBio has used its cutting edge capabilities to discover fragment inhibitors for variety of targets including kinases, protein-protein interaction, anti-virals and membrane proteins such as GPCRs and ligand gated ion channels.
For further details on this release, please contact:
Scientific Director, CellCentric
Tel: + 44 (0) 1799 531 130